A study from Michael T. Schweizer, MD, and colleagues at Johns Hopkins University in Baltimore Md. concluded that the longer the metastasis-free survival after a radical prostatectomy the longer overall survival in men who experience biochemical recurrence (PSA only recurrence) of their prostate cancer. This conclusion was made from a retrospectively study of 450 men [...]
When Angelina Jolie's double mastectomy hit the headlines in May this year there was a lot of press coverage including discussions about BRCA 1 and 2 genes. These conversations centered on women and their risk of breast or ovarian cancer. But, what about BRCA 1 and 2 in relation to prostate cancer, is there any? [...]
The exciting thing about Provenge is not only the real survival advantage that it offers with minimal side effects, but that it is a proof of concept treatment that is heralding in the potential future of many other immunotherapies. Today, we have two new possible treatments in active phase 3 trials, Prostvac and Yervoy. [...]
Dr. Farid Fata, who owns Michigan Hematology Oncology which has six offices throughout Michigan in the cities of Clarkston, Bloomfield Hills, Lapeer, Sterling Heights, Troy and Oak Park is now out of jail, but he is on bail. Why am I even telling you about this, because as usual I have an important lesson to [...]
It has been brought to my attention that when I wrote the August 8, 2013 post on Pharma Sponsored Assistance Programs, I neglected to mention another excellent assistance program for men with advanced prostate cancer. The Chronic Disease Fund (CDF) has two funds that might be of specific interest to men with castrate resistant prostate [...]